Pharmacokinetic evaluation of transdermal buprenorphine in man

Wilding, I.R.; Davis, S.S.; Rimoy, G; Rubin, Peter C.; Kurihara-Bergstrom, Tamie; Tipnis, Vijay; Berner, Bret; Nightingale, James

doi:10.1016/0378-5173(96)85198-2

Cited by 10 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…long duration of action, shallow effect curve, slow receptor dissociation rate) may also be the reason for the low addictive potential of the drug as determined in preclinical and clinical studies and as substantiated by epidemiological data (Preston and Jasinski 1991;see Cowan and Lewis 1995). The use of improved application forms such as slow release formulations, fixed combinations with naloxone (Amass et al 2001;Stoller et al 2001) or transdermal patches (Wilding et al 1996;Anon 2001) can be expected to further decrease the likelihood of buprenorphine abuse and addiction, since with these very slow applications, the temporal associations between drug taking and drug effect are even weaker than with traditional ways of drug application.…”

Section: Discussionmentioning

confidence: 98%

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke

2004

Psychopharmacology

View full text Add to dashboard Cite

The present results suggest that the reported lack of CPP effects at high doses of buprenorphine may be due to factors in the experimental design, resulting in a carry-over effect from drug- to vehicle conditioning. They also suggest that buprenorphine, like other opiates, produces its CPP effects via micro -receptors, although kappa-antagonistic mechanisms also appear to be involved. The implications of these findings for the safety of buprenorphine for human use are discussed.

show abstract

Section: Discussionmentioning

confidence: 98%

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Tzschentke

2004

Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…However, these dosing regimens had many disadvantages such as inconvenient management of chronic pain caused by the need for frequent administrations per day, and the possibility of the manifestation of drug toxicity due to sudden peaks in plasma drug concentrations. Therefore, transdermal delivery systems (TDS) have recently been introduced to overcome such disadvantages by maintaining a constant blood drug concentration at an effective level for analgesia and eliminating the frequent dosing (25)(26)(27)(28)(29)(30)(31) required for the management of chronic pain.…”

Section: Introductionmentioning

confidence: 99%

Buprederm™, a New Transdermal Delivery System of Buprenorphine: Pharmacokinetic, Efficacy and Skin Irritancy Studies

Park¹,

Kim²,

Song³

et al. 2008

Pharm Res

View full text Add to dashboard Cite

show abstract

“…Buprenorphine hydrochloride is a synthetic opiate analgesic which has a combination property of agonist and antagonist. It is used for post treatment of drug addicts, acute and chronic pains (Hutchings et al, 2007;Wilding et al, 1996).…”

Section: Introductionmentioning

confidence: 99%

Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride

Koocheki

Madaeni

Niroomandi³

2011

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

To control the minimum effective dose, and reduce the number and quantity of administered potent drugs are unique features of advanced drug delivery in situ forming gel formulation. The efficacy, consistency, and increasing the application of existing injection therapies can be enhanced through optimization of controlled released systems by using FDA approved biodegradable PLGA (poly-d,l-lactide-co-glycolide) polymer. The purpose of this study was to develop different in situ forming implant (ISFI) formulations of buprenorphine hydrochloride for post treatment of drug addicts, acute and chronic pains. The drug releases from different ISFIs membranes with and without Tween 80 were compared over a period of time. Kinetic equation followed the Korsmeyer-Peppas model, as the plots showed high linearity. The influence of this additive on polymer properties was investigated using differential scanning calorimetry (DSC), and the membranes structure was studied by X-ray diffractometry (XRD) and scanning electron microscope (SEM). Data revealed that Tween 80 modified the drug release pattern using diffusion mechanism and decreased the glass transition temperature (T g) significantly. The degree of crystallinity was decreased after phase inversion which helps the dissolution of drug from membrane. The porosity of modified membranes was in accordance with release profiles. These findings suggest four different in situ forming implant formulations which can release various dose of the buprenorphine hydrochloride in a prolonged time. Also this surfactant can be an attractive additive for modifying the release rate of drugs from PLGA-based membrane drug delivery systems.

show abstract

Pharmacokinetic evaluation of transdermal buprenorphine in man

Cited by 10 publications

References 6 publications

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations

Buprederm™, a New Transdermal Delivery System of Buprenorphine: Pharmacokinetic, Efficacy and Skin Irritancy Studies

Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride

Contact Info

Product

Resources

About